Dabigatran etexilate tosylate

达比加群酯甲苯磺酸盐

Report date: 2025/08/18 17:56:37
NME

Base Information

Drug NameDabigatran etexilate tosylate
Drug Alias NameRDG-17012
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProthrombin inhibitors
TargetsProthrombin
Therapy Area/IndicationsPostoperative HemorrhageHemorrhageAtrial Fibrillation +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesHuons Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIcahn School Of Medicine At Mount SinaiPhri Population Health Research Institute International
Inactive CompaniesHuons Co Ltd
Active IndicationsPostoperative HemorrhageHemorrhageAtrial Fibrillation +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A